What Happened?
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell 2.8% in the morning session after Wells Fargo downgraded the company's stock to 'Equalweight' from 'Overweight' and significantly lowered its price target.
The investment bank also adjusted its price forecast for the pharmaceutical company's shares, reducing it to $19 from a previous target of $30. This type of ratings change from a financial analyst often leads to a drop in a company's stock price, as it suggests a less optimistic outlook on its future performance. The lowered rating and price target signal that Wells Fargo's analyst now sees more limited potential for the stock to increase in value in the near term.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Amphastar Pharmaceuticals? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Amphastar Pharmaceuticals’s shares are quite volatile and have had 18 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 6 days ago when the stock dropped 19.1% on the news that the company reported disappointing first-quarter 2026 financial results, missing profit expectations and posting a significant decline in earnings compared to the previous year.
Amphastar's adjusted non-GAAP profit was $0.42 per share, a 43% drop from $0.74 in the same period of the prior year and a 40.5% miss on analyst estimates. While net revenues of $171.2 million were roughly flat year-over-year and slightly missed expectations, the company's profitability was hit hard.
Adjusted operating income of $22.9 million came in 47.7% below Wall Street's expectations, and its adjusted operating margin fell to 13.4%, a sharp decline of 17.1 percentage points from the same quarter last year. This contraction highlights that expenses increased relative to revenue, contributing to the poor performance.
Amphastar Pharmaceuticals is down 33.3% since the beginning of the year, and at $17.66 per share, it is trading 42.7% below its 52-week high of $30.81 from September 2025. Investors who bought $1,000 worth of Amphastar Pharmaceuticals’s shares 5 years ago would now be looking at only $884.13.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
